Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8662926rdf:typepubmed:Citationlld:pubmed
pubmed-article:8662926lifeskim:mentionsumls-concept:C0025936lld:lifeskim
pubmed-article:8662926lifeskim:mentionsumls-concept:C0019475lld:lifeskim
pubmed-article:8662926lifeskim:mentionsumls-concept:C0026845lld:lifeskim
pubmed-article:8662926lifeskim:mentionsumls-concept:C0031715lld:lifeskim
pubmed-article:8662926lifeskim:mentionsumls-concept:C1514559lld:lifeskim
pubmed-article:8662926lifeskim:mentionsumls-concept:C0205217lld:lifeskim
pubmed-article:8662926lifeskim:mentionsumls-concept:C0599781lld:lifeskim
pubmed-article:8662926lifeskim:mentionsumls-concept:C0332120lld:lifeskim
pubmed-article:8662926pubmed:issue25lld:pubmed
pubmed-article:8662926pubmed:dateCreated1996-8-13lld:pubmed
pubmed-article:8662926pubmed:abstractTextHexokinase II (HKII) is the predominant isozyme expressed in peripheral insulin-responsive tissues. To explore the role of HKII in muscle glucose metabolism, two lines of transgenic mice were generated where overexpression was restricted to striated muscle; HKII protein levels and activity were increased by 3-8-fold. Oral glucose tolerance, intravenous insulin tolerance, and insulin and lactate levels were unaffected in transgenic mice. There was a trend toward increased levels of muscle glycogen; however, glucose-6-phosphate levels were increased by 43% in transgenic skeletal muscle following in vivo glucose and insulin administration. Using 2-[3H]deoxyglucose as a tracer, in vitro basal and insulin-stimulated glucose uptake were determined in extensor digitorum longus, soleus, and epitrochlearis muscles. Maximal insulin-stimulated glucose uptake was increased by 17% (extensor digitorum longus), 34% (soleus), and 90% (epitrochlearis) in transgenic muscles; basal and submaximal glucose uptake was also modestly increased in soleus and epitrochlearis. These data suggest that increased muscle HKII (corresponding to the upper end of the physiologic range) may not be sufficient to augment net in vivo glucose homeostasis. However, glucose phosphorylation can represent a rate-limiting step for skeletal muscle glucose utilization since muscle glucose-6-phosphate levels are increased during in vivo hyperinsulinemia and hyperglycemia; furthermore, basal and insulin-mediated muscle glucose uptake can be increased by a selective increase in HKII expression.lld:pubmed
pubmed-article:8662926pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8662926pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8662926pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8662926pubmed:languageenglld:pubmed
pubmed-article:8662926pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8662926pubmed:citationSubsetIMlld:pubmed
pubmed-article:8662926pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8662926pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8662926pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8662926pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8662926pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8662926pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8662926pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8662926pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8662926pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8662926pubmed:statusMEDLINElld:pubmed
pubmed-article:8662926pubmed:monthJunlld:pubmed
pubmed-article:8662926pubmed:issn0021-9258lld:pubmed
pubmed-article:8662926pubmed:authorpubmed-author:GrannerD KDKlld:pubmed
pubmed-article:8662926pubmed:authorpubmed-author:ChangP YPYlld:pubmed
pubmed-article:8662926pubmed:authorpubmed-author:JensenJJlld:pubmed
pubmed-article:8662926pubmed:authorpubmed-author:IvyJ LJLlld:pubmed
pubmed-article:8662926pubmed:authorpubmed-author:MollerD EDElld:pubmed
pubmed-article:8662926pubmed:authorpubmed-author:PrintzR LRLlld:pubmed
pubmed-article:8662926pubmed:issnTypePrintlld:pubmed
pubmed-article:8662926pubmed:day21lld:pubmed
pubmed-article:8662926pubmed:volume271lld:pubmed
pubmed-article:8662926pubmed:ownerNLMlld:pubmed
pubmed-article:8662926pubmed:authorsCompleteYlld:pubmed
pubmed-article:8662926pubmed:pagination14834-9lld:pubmed
pubmed-article:8662926pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:meshHeadingpubmed-meshheading:8662926-...lld:pubmed
pubmed-article:8662926pubmed:year1996lld:pubmed
pubmed-article:8662926pubmed:articleTitleOverexpression of hexokinase II in transgenic mice. Evidence that increased phosphorylation augments muscle glucose uptake.lld:pubmed
pubmed-article:8662926pubmed:affiliationDepartment of Medicine, Beth Israel Hospital and Harvard Medical School, Boston, Massachusetts 02215, USA.lld:pubmed
pubmed-article:8662926pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8662926pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:8662926pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8662926lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8662926lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8662926lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8662926lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8662926lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8662926lld:pubmed